FDA Recalls Mitral Valve Delivery System Over Burst Risk

The FDA is alerting patients and providers to a recall of the Commander M system due to a balloon burst risk.

Updated on Oct. 15, 2026 in Heart Disease

Bold flat-color editorial illustration featuring a simplified heart silhouette, representing a serious medical device safety alert. — The FDA issued a recall for the Commander M mitral valve delivery system after balloon bursts caused one death and one injury. AI Illustration. Upload story photo >

The FDA issued a warning regarding the Commander M delivery system used in SAPIEN M3 transcatheter mitral valve replacement procedures. The agency recall follows reports of balloon bursts during inflation, which have been linked to one death and one serious injury.

Why it matters

The recall is a critical safety measure as these delivery systems are essential for proper valve placement, and balloon failures can lead to life-threatening complications. Patients or caregivers concerned about existing or upcoming heart procedures should consult their surgeon about the specific devices being used.

Official FDA regulatory notification records three instances of balloons bursting during inflation of the Commander M delivery system. These events resulted in one death and one serious injury as of October 5, 2026, though the underlying cause of the failures remains under investigation.

The players

Edwards Lifesciences

A medical technology company specializing in products for structural heart disease and critical care monitoring.

FDA

The United States federal agency responsible for protecting public health by ensuring the safety and efficacy of medical devices.

The details

The Commander M delivery system is designed to deploy the SAPIEN M3 transcatheter mitral valve. When the balloon bursts during inflation, it can fail to properly seat the valve or cause physical obstruction by blocking blood vessels, potentially preventing the successful retrieval of the delivery device itself. Edwards Lifesciences has directed providers to remove and return all affected inventory to mitigate further risk.

December 2025: SAPIEN M3 system received US approval.
October 5, 2026: Reported date for one death and one injury.
October 8, 2026: FDA issued a warning on Thursday.

Health Landscape

This action aligns with the FDA Medical Device Reporting (MDR) program for identifying and mitigating device risks. It marks a significant safety intervention for transcatheter valve replacement, a field that has seen rapid technological evolution since the approval of the SAPIEN M3.

Patients scheduled for mitral valve replacement should discuss the type of delivery system their surgeon intends to use. If you have recently undergone a procedure using the SAPIEN M3 system, contact your cardiologist if you experience any unexpected post-procedural symptoms.

The takeaway

Device recalls are a standard part of the safety monitoring process for complex cardiovascular tools. Always clarify the specific models of medical devices used in your care and monitor your recovery closely for any new or worsening symptoms following surgery.